FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

(Reuters) – AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *